New treatment approach for liver cancer using enhanced cellular stress mechanisms
Novel Approach to Hepatocellular Carcinoma Treatment through Enhanced ER Stress
This study is testing a new treatment for liver cancer that uses a special molecule to help make cancer cells die while keeping healthy cells safe, and it's designed for people with hepatocellular carcinoma.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11070574 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for hepatocellular carcinoma (HCC), a severe form of liver cancer. The approach targets the endoplasmic reticulum (ER) stress response in cancer cells, which is often elevated in HCC. By using a small molecule called ERX-315, the study aims to further activate this stress response, leading to cancer cell death while sparing normal cells. The research employs advanced techniques like CRISPR to identify key proteins involved in this process, specifically targeting lysosomal acid lipase A (LIPA).
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced hepatocellular carcinoma who have limited treatment options.
Not a fit: Patients with early-stage liver cancer or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with advanced liver cancer.
How similar studies have performed: Other research has shown promise in targeting cellular stress responses in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Baker, Adriana — University of Texas Hlth Science Center
- Study coordinator: Baker, Adriana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.